Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$103.91 USD

103.91
8,283,452

-0.74 (-0.71%)

Updated Jun 28, 2024 04:00 PM ET

After-Market: $103.92 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?

Abbott (ABT) poised to ride high on continued growth in EPD and Medical Devices business in Q4.

    Abbott's (ABT) Diabetes Care Unit Strong on FreeStyle Libre

    Abbott (ABT) forges ahead with initiatives to boost diabetes care. The latest CMS recognition will widen customer base for FreeStyle Libre glucose monitoring system.

      Abbott Boosts Diagnostics Arm With Alinity H-Series Launch

      Abbott (ABT) adopts initiatives to strengthen hold in the high-potential diagnostics market.

        The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum

        The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum

          Abbott (ABT) at a 52-Week High: What's Driving the Stock?

          Abbott's (ABT) successful closure of the Alere acquisition after a prolonged legal battle has boosted investor confidence.

            Intersect ENT (XENT) SINUVA Implant Receives FDA Approval

            Intersect ENT's (XENT) consistent focus on the chronic sinusitis market is likely to lend the company a competitive edge in the niche space.

              Global In Vitro Diagnostic Market Booms: Stocks in Focus

              With the emergence of complex and transmittable diseases worldwide, In Vitro Diagnostic within the MedTech space is currently in the spotlight.

                DexCom-Lily Partnership to Boost CGM Platform, Customer Base

                DexCom (DXCM) continues to sign deals to boost CGM platform adoption.

                  HCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps View

                  HCA Healthcare's (HCA) third quarter witnesses increase in revenues and admissions. However, expenses too escalate. The company reiterates guidance provided earlier this month.

                    Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2

                    Abiomed's (ABMD) strong performance in Impella heart pump boosted the company's second-quarter 2018 results.

                      Integra LifeSciences (IART) Misses on Q3 Earnings & Revenues

                      Integra LifeSciences' (IART) raised full-year 2017 revenue guidance buoys optimism.

                        Align Technology (ALGN) Q3 Earnings Top on Invisalign Sales

                        An extremely strong summer teen season drives Align Technology's (ALGN) Invisalign growth within the global teen market in the third quarter.

                          Chemed (CHE) Beats on Q3 Earnings & Revenues, View Revised

                          Chemed (CHE) rides high on its Roto-Rooter business in Q3

                            ResMed (RMD) Q1 Earnings Top on Growth in All Business Lines

                            ResMed (RMD) delivers a promising Q1 on the back of solid contributions from domestic and international businesses.

                              Stryker (SYK) Earnings and Revenues Beat Estimates in Q3

                              Stryker (SYK) posted strong numbers in the third quarter owing to higher revenues.

                                Cerner (CERN) Misses on Q3 Earnings, Bookings Decline Y/Y

                                Despite a tepid third quarter, Cerner's (CERN) bookings guidance for the fourth quarter is encouraging.

                                  Varian Medical (VAR) Misses on Q4 Earnings, Issues FY18 View

                                  Year-over-year decline in Varian Medical's (VAR) proton therapy segment is the primary cause behind the company's lackluster fourth-quarter performance.

                                    GNC Holdings (GNC) Lags Q3 Earnings & Revenues, Margins Down

                                    GNC Holdings (GNC) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from the recent hurricanes and lower sales at the U.S. & Canada and manufacturing/wholesale segments.

                                      Cardiovascular Systems (CSII) Q1 Earnings Top, Revenues Lag

                                      Cardiovascular Systems' (CSII) Q1 revenues declined year over year owing to the decline in revenues at both the segments.

                                        Boston Scientific's (BSX) Q3 Earnings In Line, Guidance Up

                                        Despite back-to-back natural disasters, Boston Scientific managed to register strong year-over-year increase in both earnings and revenues in the third quarter on balanced growth across all segments.

                                          McKesson (MCK) Beats Earnings & Revenue Estimates in Q2

                                          McKesson (MCK) reported strong second-quarter numbers owing to stable performance from Distribution Solutions business.

                                            Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.

                                            Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.

                                              Thermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance Up

                                              On solid third-quarter performance, a favorable foreign exchange environment and the recently closed acquisition of Patheon, Thermo Fisher (TMO) has raised its full-year 2017 guidance.

                                                LabCorp (LH) Beats Q3 Earnings Estimates, Raises Guidance

                                                Banking on strong third-quarter show and considering a gradually improving foreign exchange scenario, LabCorp (LH) increased its earlier provided 2017 outlook.

                                                  Walgreens Boots (WBA) Tops Q4 Earnings, Issues 2018 View

                                                  Walgreens Boots (WBA) surpasses the Zacks Consensus Estimate for both the counts in Q4 on continued prescription growth and strength in the Retail Pharmacy USA division.